aMoon

aMoon operates across the full HealthTech lifecycle. The firm's venture strategy covers early-stage, seed, and startup investments, while its growth equity vehicles target expansion and late-stage companies. This structure is designed to provide continuity of capital from initial product development through commercial scaling.

aMoon is a pure-play HealthTech investor. The firm does not diversify into enterprise software, fintech, consumer internet, or other technology verticals. Its entire mandate is concentrated within healthcare services, digital health, and life sciences ventures emerging primarily from Israel's innovation ecosystem.

aMoon's headquarters are in Ra'anana, and the firm's core sourcing model is anchored in Israel's academic and medical research institutions. While the firm targets companies with global regulatory strategies and international commercial ambitions, detailed geographic allocation data is not disclosed.

aMoon functions as a multi-fund private equity manager. It operates separate early-stage venture vehicles alongside dedicated growth equity funds. This dual-fund architecture distinguishes it from single-fund health VCs and from large generalist growth platforms that treat healthcare as one of many sectors.

Available information describes aMoon as a direct investor in private companies across venture and growth stages. There is no public disclosure of a fund-of-funds program or limited partner commitments to external PE or VC managers.

No. aMoon does not publish an AUM figure, and no specific number has appeared in regulatory filings or media reports accessible for this review. The firm's financial scale is not publicly verifiable.

No disclosed philanthropic foundations or donor-advised vehicles are associated with aMoon or its principals in the available materials. The entity appears strictly operational as a private equity investment firm.